4 in 1 casino game table Palvella Therapeutics to debut on Nasdaq under the ticker symbol “PVLA” as a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic diseases Strong balance sheet with approximately $80.0 million of cash and cash equivalents, including proceeds from a PIPE financing co-led by BVF Partners, L.P. and Frazier Life Sciences Cash expected to fund operations into the second half of 2027, including through Phase 3 SELVA clinical trial of QTORINTM 3.9% rapamycin anhydrous gel (QTORINTM rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs) and Phase 2 clinical trial in cutaneous venous malformations (cutaneous VMs) Microcystic LMs is a chronically debilitating and lifelong genetic disease affecting an estimated more than 30,000 diagnosed patients in the U.S. QTORINTM rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for microcystic LMs and cutaneous VMs WAYNE, Pa., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced the completion of its previously announced merger with Pieris Pharmaceuticals, Inc. (Pieris). The combined company will operate under the name Palvella Therapeutics, Inc., and its shares are expected to begin trading on the Nasdaq Capital Market on December 16, 2024, under the ticker symbol "PVLA". Palvella will continue to be led by Wes Kaupinen, its Founder and Chief Executive Officer, and other members of the Palvella management team. The transaction was approved by Pieris stockholders at a special meeting held on December 11, 2024, and the transaction had been previously approved by Palvella stockholders. "With strong support from leading healthcare-dedicated investors, Palvella is well positioned to enter the public markets and pursue our vision of becoming the leading rare disease company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases," said Mr. Kaupinen. “This transaction will enable us to accelerate late-stage development of QTORINTM rapamycin, our lead product candidate, for microcystic LMs and cutaneous VMs while also further advancing additional novel product candidates from our QTORINTM platform." Concurrent with the merger, Palvella completed a previously announced oversubscribed $78.9 million private placement co-led by BVF Partners, L.P., an existing investor, and Frazier Life Sciences, a new investor, and with participation from a syndicate of leading healthcare-dedicated investors. Additional new investors include Blue Owl Healthcare Opportunities, Nantahala Capital, DAFNA Capital Management, ADAR1 Capital Management, and a healthcare dedicated fund. Existing investors Samsara BioCapital, Petrichor, CAM Capital, Ligand Pharmaceuticals, Integrated Finance Group (an AscellaHealth partner company), BioAdvance, and Gore Range Capital also participated in the financing. Palvella's cash and cash equivalents of approximately $80.0 million is expected to fund operations into the second half of 2027, including through results from the SELVA Phase 3 clinical trial of QTORINTM rapamycin for the treatment of microcystic LMs and Phase 2 clinical trial of QTORINTM rapamycin in cutaneous VMs. Palvella’s research team developed QTORINTM, a patented and versatile platform designed to generate novel topical therapies that penetrate the deep layers of the skin to locally treat a broad spectrum of serious, rare genetic skin diseases. Well-accepted mechanisms of action of rapamycin and other therapeutic agents represent potential therapies for rare genetic skin diseases. However, the adverse event profile of those agents through systemic exposure poses significant barriers to patient adoption. Palvella’s QTORINTM product candidates are designed for targeted, localized delivery of therapeutic agents to pathogenic tissue of interest while minimizing systemic absorption and thereby reducing the risk of unwanted adverse events associated with systemic therapy. Palvella's lead product candidate QTORINTM rapamycin is a novel, patented 3.9% rapamycin anhydrous gel currently under development for the treatment of microcystic LMs, cutaneous VMs, and other serious, functionally debilitating skin diseases driven by the overactivation of the mammalian target of rapamycin (mTOR) pathway. QTORINTM rapamycin has received FDA Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation for microcystic LMs and is the recent recipient of up to a $2.6 million FDA Orphan Products Grant. QTORINTM rapamycin has also received Fast Track Designation for venous malformations. QTORINTM rapamycin is protected by issued composition patents covering anhydrous gel formulations of rapamycin, as well as methods of use, in the U.S., Japan, Australia, China and Israel and pending patent applications broadly covering anhydrous gel formulations of rapamycin, as well as methods of use, in the U.S. and other countries. In the third quarter of 2024, Palvella initiated SELVA, a 24-week, Phase 3, single-arm, baseline-controlled clinical trial of QTORINTM rapamycin administered once daily for the treatment of microcystic LMs. The primary efficacy endpoint is the change from baseline in the overall microcystic LM Investigator Global Assessment (mLM-IGA) at week 24. The Phase 3 study is enrolling approximately 40 subjects, age six or older, at leading vascular anomaly centers across the U.S. Transaction Details Based on the final exchange ratio of approximately 0.30946 shares of Pieris common stock for each share of Palvella common stock, at the closing of the merger, there are approximately 13.95 million shares of the combined company's common stock outstanding on a diluted basis, with prior Pieris stockholders owning approximately 11% on a diluted basis and prior Palvella stockholders (including investors in the private placement) holding approximately 89% of the combined company's outstanding common stock on a diluted basis. In connection with the closing of the merger, Pieris issued a non-transferable contingent value right (CVR) to Pieris shareholders of record immediately prior to the closing, which does not include the former holders of shares of Palvella or the private financing investors. Holders of the CVR will be entitled to receive payments from proceeds received by the combined company, if any, under Pieris' existing partnership agreements with Pfizer and Boston Pharmaceuticals, in addition to other potential licensing agreements involving certain of Pieris' legacy assets, as well as certain potential payments related to historical research and development tax credits, which may or may not be realized. TD Cowen served as lead placement agent and Cantor served as a placement agent for Palvella's concurrent financing. Troutman Pepper Hamilton Sanders LLP served as legal counsel to Palvella. Cooley LLP served as legal counsel to the placement agents. Stifel served as the exclusive financial advisor to Pieris and Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C. served as legal counsel to Pieris. About Microcystic Lymphatic Malformations Microcystic LMs are a rare, chronically debilitating genetic disease caused by dysregulation of the phosphatidylinositol 3-kinase (PI3K)/mTOR pathway. The disease is characterized by malformed lymphatic vessels that protrude through the skin and persistently leak lymph fluid (lymphorrhea) and bleed, often leading to recurrent serious infections and cellulitis that can cause hospitalization. The natural history of microcystic LMs are persistent and progressive without spontaneous resolution, with symptoms generally worsening during life, including increases in the number and size of malformed vessels that lead to complications and lifetime morbidity. There are currently no FDA-approved treatments for the estimated more than 30,000 diagnosed patients with microcystic LMs in the United States. About Palvella Therapeutics Founded and led by rare drug disease drug development veterans, Palvella Therapeutics (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORINTM platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella’s lead product candidate, QTORINTM 3.9% rapamycin anhydrous gel (QTORINTM rapamycin), is currently in the Phase 3 SELVA clinical trial in microcystic lymphatic malformations (microcystic LMs) and a Phase 2 trial in cutaneous venous malformations. For more information, please visit www.palvellatx.com or follow the Company on LinkedIn. QTORINTM rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency. This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (Securities Act)). These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Palvella and Pieris, as well as assumptions made by, and information currently available to, management of Palvella and Pieris. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Statements that are not historical facts are forward-looking statements. Forward-looking statements include, but are not limited to, the sufficiency of the combined company’s capital resources; the combined company’s cash runway; the expected timing of the closing of the proposed transactions; statements regarding the potential of, and expectations regarding, Palvella’s programs, including QTORINTM rapamycin, and its research-stage opportunities, including its expected therapeutic potential and market opportunity; the expected timing of initiating, as well as the design of Palvella’s Phase 2 clinical trial of QTORINTM rapamycin in cutaneous venous malformations. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the limited operating history of each company; the significant net losses incurred since inception; the ability to raise additional capital to finance operations; the ability to advance product candidates through preclinical and clinical development; the ability to obtain regulatory approval for, and ultimately commercialize, Palvella’s product candidates, including QTORINTM rapamycin; the outcome of early clinical trials for Palvella’s product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements; the fact that data and results from clinical studies may not necessarily be indicative of future results; Palvella’s limited experience in designing clinical trials and lack of experience in conducting clinical trials; the ability to identify and pivot to other programs, product candidates, or indications that may be more profitable or successful than Palvella’s current product candidates; the substantial competition Palvella faces in discovering, developing, or commercializing products; the negative impacts of the global events on operations, including ongoing and planned clinical trials and ongoing and planned preclinical studies; the ability to attract, hire, and retain skilled executive officers and employees; the ability of Palvella and Pieris to protect their respective intellectual property and proprietary technologies; reliance on third parties, contract manufacturers, and contract research organizations. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in Pieris’ most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC, as well as the registration statement on Form S-4 filed with the SEC by Pieris in connection with the merger. Palvella and Pieris can give no assurance that the conditions to the proposed transactions will be satisfied. Except as required by applicable law, Palvella and Pieris undertake no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release. Palvella Therapeutics Contact Information Investors Wesley H. Kaupinen Founder and CEO, Palvella Therapeutics wes.kaupinen@palvellatx.com Media Stephanie Jacobson Managing Director, Argot Partners palvella@argotpartners.comNone

Larson Financial Group LLC Increases Position in Johnson Controls International plc (NYSE:JCI)

Media Delegations Visit Book Fair GroundFor some people, symptoms of seasonal affective disorder can be severe and they can have a significant impact on day-to-day life. Now health experts have outlined some ways to combat SAD during the winter months. The NHS says SAD is sometimes known as "winter depression" because the symptoms are usually more apparent and more severe during the winter. However, people may have symptoms during the summer and feel better during the winter. "The exact cause of SAD is not fully understood but it's often linked to reduced exposure to sunlight during the shorter autumn and winter days," the NHS explains. The main theory is that a lack of sunlight might stop a part of the brain called the hypothalamus working properly, which may affect the production of melatonin and serotonin as well as the body's internal clock. It's also possible that some people are more vulnerable to SAD as a result of their genes, as some cases appear to run in families. Below are the main symptoms of SAD, followed by tips on how to deal with it. Symptoms of SAD According to the NHS, symptoms of SAD can include: a persistent low mood a loss of pleasure or interest in normal everyday activities irritability feelings of despair, guilt and worthlessness feeling lethargic (lacking in energy) and sleepy during the day sleeping for longer than normal and finding it hard to get up in the morning craving carbohydrates and gaining weight difficulty concentrating decreased sex drive Keep up to date with all the latest breaking news and top stories from the North East with our free newsletter Fatih Mustafa Çelebi, co-founder and CEO of Meditopia , has given the following tips to help you combat these feelings during the winter. Fatih said: "Seasonal affective disorder is more common than people think, and many may not even realise that it’s what they’re experiencing each year. Because symptoms tend to improve after a few months, many people go undiagnosed. "These tips aren’t meant to be a miracle cure, but will hopefully ease the impact of SAD. If your symptoms become unmanageable, don’t hesitate to reach out to friends, family, or a healthcare professional to explore treatment options. Remember, there’s no shame in seeking help, and early intervention can make a big difference." Leave the house One of the best and most effective ways to combat any form of depression is exercise. Although it can be tough to persevere in the colder months, the benefits are hard to deny. Fatih says that wrapping up warm and going for a walk is more than enough, ideally when there’s still some light outside. Listen to your favourite music, or pop on an interesting podcast and take a stroll around your neighbourhood. It can be as little as five minutes or as long as a few hours, but getting your body moving, having a change of scenery, and soaking up some well-needed sunlight will all help to fight off symptoms of SAD. Bringing a friend can be beneficial too, as when we start to feel depressed, it’s easy to become isolated. Grab a hot drink and use this time as an opportunity to catch up with a loved one. Get ahead of the curve If you know you suffer from SAD, it’s a good idea to prepare before the symptoms set in. Fatih recommends making a few concrete plans for the months when depression tends to affect you. These activities could be exciting and social, relaxing and personal, or a mix of both. He also warns that when you're feeling depressed, it's easy to lose motivation, so planning things you'll genuinely enjoy when you're mentally well gives you something to look forward to. Additionally, it may help to reschedule stressful activities and stock up on essential items, so you don’t need to go out and buy them later. Letting friends and family know how you feel ahead of time will also make a difference. It can be hard to reach out in the moment, so making your support network aware that you may struggle in the coming months will put less pressure on you, and ensure you’re still involved in daily conversations. Create a routine Although it's hard, creating a routine and sticking to it will help you immensely. Waking up at a set time or within a set time frame, making a nice drink, and taking a few moments to set yourself up for the day can be extremely beneficial. Create a small list of goals you want to achieve in your day and tick them off as you go. Try not to make the list too big, as that could overwhelm you. Going to bed at the same time each day will help your body clock to regulate itself, and make sure you’re getting enough sleep every day. Fatih suggests starting this routine early, as it will be far easier to stick to when winter is in full swing. Other top tips: Introduce more light into your environment – opening the curtains earlier, lighting a candle, or getting some battery-powered fairy lights can all combat the dark, with the latter two options also adding an element of cosiness into your home. Keep a diary – this can help you identify what triggers your feelings and provides a private outlet to voice your feelings without being judged. Try to keep a balanced diet – whilst it’s fine to drown your feelings in chocolate every now and then, try not to make a habit of it. Make sure you eat the right amount for your body and enjoy all foods in moderation. Try light therapy - this is a treatment using a special light box, known as a SAD light, that mimics sunlight. The UV light is filtered out to prevent skin and eye damage, while the bright light stimulates the hypothalamus to lower melatonin and boost serotonin production. ChronicleLive is now on WhatsApp and we want you to join our communities. We have a number of communities to join, so you can choose which one you want to be part of and we'll send you the latest news direct to your phone. You could even join them all! To join you need to have WhatsApp on your device. All you need to do is choose which community you want to join, click on the link and press 'join community'. No one will be able to see who is signed up and no one can send messages except the ChronicleLive team. We also treat our community members to special offers, promotions, and adverts from us and our partners. If you don't like our community, you can check out any time you like. To leave our community click on the name at the top of your screen and choose 'exit group'. If you’re curious, you can read our privacy notice . Join the ChronicleLive Breaking News and Top Stories community Join our Court & Crime community Join the Things to do in Newcastle and the North East community Join our Northumberland community Join our County Durham community Join our Sunderland community Join our NUFC community Join our SAFC community Join our Great North Run community

Honda’s 12-inch robot talks to people with facial expressions, speeds up tasks by 900%One in five Brits pick holiday destinations in the hope of seeing a . Travel agents say ET hotspots worldwide are rocketing in popularity. A new poll has revealed 28% of Brits believe in . One in five claims already to have seen a . A quarter admit they are more likely to visit destinations known for close encounters. While one in five say they are "eager to explore UFO hotspots this year". Online travel operator Opodo has identified 35 of the world’s leading UFO hotspots to offer alien-hunters the chance to combine "stunning natural beauty" with a `history of sightings’. No1 is The Valley of Fire in Nevada, US, where there have been 18 official UFO sightings. Most are described as "fireballs" and typically orange or green. Opodo says the state park "gives an extraterrestrial feel with its vibrant hues of red and orange along with the unique rock formations creating an otherworldly atmosphere reminiscent of Mercury’s rugged terrain". It is followed by Death Valley in California which boasts 17 sightings most of which are "oval" crafts. One account describes a "UFO that splits into two and later takes off emitting a blue streak". The desert valley is one of the hottest places on Earth. Vatnajökull Glacier in Iceland boasts 14 sightings most of which are reported as crafts. Renowned for its exceptional stargazing conditions visitors can experience breathtaking displays of the Northern Lights and - on clear nights without auroras - views of the Milky Way. An Opodo spokesman said: ``Over the past few years there has been a huge surge in interest in the extraterrestrial which has been driven by a combination of recent government disclosures and technological advances. "From the US declassifying reports and videos of UFO encounters to the upcoming launch of NASA’s Europa Clipper in October 2024, which aims to explore potential signs of life on Jupiter’s moon, the fascination with space and the unknown is reaching new heights.’" The tour operator polled 1,500 UK holidaymakers in a bid to understand the growing interest in extraterrestrial experiences. "The survey revealed that 28% of respondents believe in aliens,’’ the spokesman said. "One in five state they have seen a UFO with this number soaring to one in three for those under 34-years-old. "One in five holidaymakers are eager to explore UFO hotspots this year." A third of people believe they will be able to holiday in space within their lifetime and 11% would jump at the opportunity. The planets they would be most interested in visiting include Mars (23%), Saturn (8%) and Jupiter (7%). The survey comes after US defence chiefs finally admitted UFOs are reveal - though they said they had not found any evidence the mystery craft were controlled by extraterrestrials.

Bears interim coach Thomas Brown insists he's focused on task at hand and not what his future holds

Holiday shopping season separates winning retailers from losers

Larson Financial Group LLC Increases Position in Johnson Controls International plc (NYSE:JCI)

Arguments over whether Luigi Mangione is a 'hero' offer glimpse into unusual American moment

Local borrowing at 45%, economy stable with $200m current account surplus: SBPAaron Judge joins legendary Yankees list with 2nd MVP AwardFormer San Jose mayor celebrated at rotunda naming ceremony

Sweeping deportations pledged by President-elect Donald Trump could pose an economic shock for the restaurant industry in ways that echo the pandemic: pricier menus, rising wages and shuttered storefronts, economists and some restaurateurs worry. But Wall Street is wagering that Trump’s tough talk is a bluff ahead of a more limited crackdown that won’t uproot the restaurant industry’s immigrant-heavy workforce. The industry is one of the most reliant on workers in the country illegally, making it a test case for whether Trump will fulfill completely his campaign promises. “I see little risk of them deporting people that are working at jobs in restaurants or anywhere else in the food industry,” says Dan Ahrens, chief operating officer and portfolio manager of AdvisorShares. Ahrens said he believes Trump’s administration will focus on immigrant criminals, with talk of broader deportations amounting to political rhetoric. Thomson Reuters' index of restaurant and bar stocks has steadily risen more than 5% since the election, outpacing the S&P 500. In the last year, while lagging the S&P, restaurant stocks have risen nearly 10%, buoyed by rising prices sectorwide even as consumers are eating out less. Holiday deals: Shop this season’s top products and sales curated by our editors. Gary Bradshaw, portfolio manager at Hodges Capital Management, said he remains bullish on restaurants with growing sales revenue and store numbers, like Chipotle, McDonald's and Texas Roadhouse. On the prospect of deportations, he said, “My guess is the bark is a lot louder than the bite, but hey, nobody knows. So I don’t spend a whole lot of time thinking about it.” More: The US is short millions of housing units. Mass deportations could make it worse. Jake Dollarhide, chief executive of Longbow Asset Management, said he doesn’t make investment decisions on hypothetical policy. “We didn’t sell our energy stocks the day Joe Biden took office,” he said. He said he believed stock market highs and the "propensity of Americans to spend" would continue to drive restaurant stocks up. "The perception of grocery inflation — whether real or not real — benefits restaurants," he added. Trump has said that the initial focus of deportations will be on criminals in the U.S. illegally, but that the net will eventually widen to all immigrants in the country illegally. “I think you have to do it,” he told NBC last weekend. Around 1-in-12 of the country’s 10 million restaurant workers were living in the United States illegally in 2022, according to Pew Research Center estimates from this summer which have not previously been published. “Restaurants will be a hard-hit sector,” if Trump lives up to his promises on deportations, said Marcus Noland, an economist with the Peterson Institute for International Economics. Not only will they have to contend with their own higher labor costs, Noland said, but they’ll also have to pay more for food because of disruptions upstream in agriculture. “You saw this during the pandemic when many restaurants had restricted hours, smaller menus and worse service,” he said. PIIE estimated prices in the service sector would rise 1.7% if the Trump administration deported 1.3 million workers, or to rise 11% if the administration fulfilled its commitment of deporting all working immigrants in the country illegally, which the Pew Center estimates at 8.3 million. “We’re already dealing with a huge labor shortage of food workers," said Jacob Monty, an immigration and employment lawyer who advises chain restaurants. "If you add more enforcement, it’s going to only get harder to find workers to staff restaurants.” Diners are already reeling from sticker shock, and Kelsey Erickson Streufert, the Texas Restaurant Association’s chief policy liaison, said restaurateurs in the state are concerned that a “tipping point” has been reached for raising prices. “Customers are only going to pay so much for a hamburger,” she said. Reporting by Waylon Cunningham; Editing by Peter Henderson and Alistair Bell

Arguments over whether Luigi Mangione is a 'hero' offer glimpse into unusual American moment

Mutual of America Capital Management LLC grew its position in Teradyne, Inc. ( NASDAQ:TER – Free Report ) by 2.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 20,089 shares of the company’s stock after buying an additional 404 shares during the period. Mutual of America Capital Management LLC’s holdings in Teradyne were worth $2,691,000 as of its most recent SEC filing. Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Swedbank AB boosted its position in shares of Teradyne by 198.8% during the second quarter. Swedbank AB now owns 641,614 shares of the company’s stock valued at $95,145,000 after buying an additional 426,900 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its stake in Teradyne by 18.2% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,432,722 shares of the company’s stock valued at $325,814,000 after acquiring an additional 374,522 shares during the period. Healthcare of Ontario Pension Plan Trust Fund boosted its holdings in shares of Teradyne by 4,695.9% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 290,249 shares of the company’s stock valued at $43,041,000 after acquiring an additional 284,197 shares during the last quarter. Driehaus Capital Management LLC bought a new stake in shares of Teradyne in the second quarter worth approximately $41,467,000. Finally, Principal Financial Group Inc. raised its holdings in shares of Teradyne by 105.2% during the second quarter. Principal Financial Group Inc. now owns 527,417 shares of the company’s stock valued at $78,211,000 after purchasing an additional 270,396 shares during the last quarter. Institutional investors own 99.77% of the company’s stock. Insider Buying and Selling at Teradyne In other Teradyne news, Director Mercedes Johnson sold 625 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $133.49, for a total transaction of $83,431.25. Following the completion of the transaction, the director now owns 16,518 shares of the company’s stock, valued at $2,204,987.82. This represents a 3.65 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website . Also, insider Richard John Burns sold 789 shares of the firm’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $132.80, for a total value of $104,779.20. Following the transaction, the insider now owns 21,864 shares of the company’s stock, valued at approximately $2,903,539.20. The trade was a 3.48 % decrease in their position. The disclosure for this sale can be found here . Insiders sold a total of 8,199 shares of company stock valued at $1,080,634 in the last three months. 0.36% of the stock is currently owned by corporate insiders. Teradyne Price Performance Teradyne ( NASDAQ:TER – Get Free Report ) last issued its quarterly earnings results on Wednesday, October 23rd. The company reported $0.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.78 by $0.12. Teradyne had a return on equity of 18.56% and a net margin of 18.75%. The business had revenue of $737.30 million during the quarter, compared to analyst estimates of $716.40 million. During the same quarter in the prior year, the business posted $0.80 EPS. Teradyne’s revenue for the quarter was up 4.8% compared to the same quarter last year. On average, research analysts expect that Teradyne, Inc. will post 3.17 EPS for the current year. Teradyne declared that its board has approved a share repurchase plan on Monday, November 11th that permits the company to buyback $100.00 million in shares. This buyback authorization permits the company to purchase up to 0.6% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board believes its shares are undervalued. Teradyne Dividend Announcement The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 18th. Shareholders of record on Monday, November 25th will be paid a $0.12 dividend. The ex-dividend date of this dividend is Monday, November 25th. This represents a $0.48 annualized dividend and a yield of 0.44%. Teradyne’s payout ratio is 15.24%. Wall Street Analysts Forecast Growth Several equities research analysts recently issued reports on the stock. Robert W. Baird dropped their target price on shares of Teradyne from $140.00 to $133.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. StockNews.com raised Teradyne from a “sell” rating to a “hold” rating in a report on Sunday, October 27th. Stifel Nicolaus reduced their price objective on Teradyne from $140.00 to $125.00 and set a “hold” rating for the company in a research report on Friday, October 25th. Cantor Fitzgerald raised Teradyne from a “neutral” rating to an “overweight” rating and set a $160.00 target price on the stock in a research report on Friday, August 16th. Finally, Craig Hallum reduced their price target on shares of Teradyne from $124.00 to $111.00 and set a “hold” rating for the company in a research report on Friday, October 25th. One analyst has rated the stock with a sell rating, six have given a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, Teradyne presently has a consensus rating of “Hold” and a consensus target price of $142.62. Read Our Latest Research Report on TER Teradyne Company Profile ( Free Report ) Teradyne, Inc designs, develops, manufactures, and sells automated test systems and robotics products worldwide. It operates through four segments; Semiconductor Test, System Test, Robotics, and Wireless Test. The Semiconductor Test segment offers products and services for wafer level and device package testing of semiconductor devices in automotive, industrial, communications, consumer, smartphones, cloud, computer and electronic game, and other applications. Featured Articles Want to see what other hedge funds are holding TER? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teradyne, Inc. ( NASDAQ:TER – Free Report ). Receive News & Ratings for Teradyne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teradyne and related companies with MarketBeat.com's FREE daily email newsletter .

A Denver City Council committee on Wednesday advanced a measure that would ban sales of most flavored tobacco and nicotine products in the city, despite strong objections from the industry and retailers that sell e-cigarettes and vapes. The council’s Safety, Housing, Education & Homelessness Committee voted 6-1 to move the ban on for consideration at the full council. The final vote would be the second attempt to pass a flavored tobacco ban in the last three years. The measure would ban nearly every kind of flavored tobacco and nicotine product from being sold within the city’s borders, including menthol cigarettes and flavored e-cigarettes and vapes. The goal, according to the ordinance’s sponsors, is to protect the health of young people. Retailers — including Phil Guerin, the owner of vape shop Myxed Up Creations, which has a Denver location — argued the ban would punish law-abiding business owners who do not sell to underage customers and would deprive the city of millions in sales tax revenues. Colorado law sets the minimum age for tobacco products at 21. The proposed ordinance was introduced in late October , but its progress was delayed through November while sponsors met with industry representatives and incorporated feedback. The updated ordinance discussed Wednesday exempts flavored tobacco smoked out of hookah pipes, a common practice in Middle Eastern and North African cultures. The ordinance, including the hookah exemption, closely mirrors the progress of a similar ban that the council passed in 2021. Then-Mayor Michael Hancock vetoed that law , arguing that Denver acting alone — while surrounding municipalities continued to allow sales of flavored products — would not keep tobacco out of the hands of kids. His successor, Mike Johnston, has affirmed his support for the flavor ban if it passes. A public hearing is possible later this month before the full body votes on the measure. Stay up-to-date with Colorado Politics by signing up for our weekly newsletter, The Spot.Thrivent Financial for Lutherans Has $5.30 Million Holdings in Sonoco Products (NYSE:SON)